ARCT - Arcturus Therapeutics GAAP EPS of -$1.98 misses by $1.81 revenue of $10.52M misses by $38.81M
2023-08-07 16:17:08 ET
- Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q2 GAAP EPS of -$1.98 misses by $1.81 .
- Revenue of $10.52M (-61.2% Y/Y) misses by $38.81M .
- Cash, cash equivalents and restricted cash were $380.6 million as of June 30, 2023 and $394.0 million on December 31, 2022. We have collected approximately $300.0 million in upfront payments and milestones from CSL Seqirus as of June 30, 2023.
- Shares -3.19% .
For further details see:
Arcturus Therapeutics GAAP EPS of -$1.98 misses by $1.81, revenue of $10.52M misses by $38.81M